Table 2 Predictors of time to diabetic neuropathy among newly diagnosed T2DM patients in UGCSH, January 2001–February 2019

Gender

 Female

45

233

1

1

 Male

32

153

1.18 [0.74, 1.87]

1.16 [0.70, 1.84]

Age

 45–49

10

74

1

1

 30–34

1

5

1.57 [0.20,12.30]

2.16 [0.27, 17.26]

 35–39

6

25

1.57 [0.57, 4.36]

2.15 [0.76, 6.13]

 40–44

6

44

0.74 [0.25, 2.19]

0.87 [0.29, 2.58]

 50–54

12

65

1.22 [0.52, 2.83]

1.29 [0.54, 3.05]

 55–59

11

64

1.34 [0.56, 3.18]

1.36 [0.57, 3.25]

 60–64

12

49

1.40 [0.59, 3.33]

1.02 [0.41, 2.54]

 65–69

14

31

3.14 [1.38, 7.16]

2.78 [1.20, 6.46]

 > 70

5

29

1.66 [0.56, 4.89]

1.08 [0.34, 3.39]

Duration of DM

 5–9

35

187

1

1

 0–4

67

15

3.20 [1.64, 6.26]

3.77 [1.82, 7.76]

 10–14

22

110

0.45 [0.25, 0.81]

0.43 [0.24, 0.80]

 > 14

5

22

0.45 [0.25, 0.81]

0.29 [0.09, 0.87]

Hypertension

 No

55

301

1

1

 Yes

22

85

1.06 [0.64, 1.75]

0.74 [0.36, 1.51]

Anemia

 No

62

364

1

1

 Yes

22

15

3.16 [1.79, 5.58]

3.82 [1.66, 8.82]

Other DM complication

 No

34

251

1

1

 Yes

43

135

1.82 [1.15, 2.88

1.68 [1.03, 2.76]

Baseline medication

 One oral agent

47

249

1

1

 Dietary modification

4

25

0.80 [0.29, 2.23]

1.13 [0.39, 3.27]

 > 1 Oral agent

17

62

2.27 [1.28, 4.01]

1.63 [0.89, 2.97]

 Insulin

9

50

1.01 [0.49, 2.07]

0.76 [0.36, 1.60]

SBP

 ≤ 140

62

313

1

1

 > 140

15

73

0.89 [0.50, 1.57]

0.94 [0.46, 1.92]

DBP

 ≤ 90

69

344

1

1

 > 90

8

42

0.77 [0.37, 1.61]

1.30 [0.51, 3.32]